Long-term results of patients with advanced diffuse, non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, prednisone and bleomycin (CHOP-Bleo).
17 patients with diffuse non-Hodgkin's lymphoma with unfavorable histologies were treated with cyclophosphamide, hydroxyldaunorubicin (doxorubicin), vincristine (Oncovin), prednisone and bleomycin (CHOP-Bleo). Of the 16 patients entering a complete remission, 8 remain in remission at 46+, 50+, 51+, 61+, 61+, 61+ and 63+ months. There were 2 treatment deaths in elderly patients, both in remission. 2 of the early relapses (less than 12 months) were later characterized as lymphoblastic lymphoma upon review of the original pathology. All 3 patients with late relapses (32, 37, and 44 months), were able to be successfully retreated. The 2 patients with lymphoblastic lymphoma developed central nervous system disease despite prophylactic intrathecal methotrexate; but central nervous system disease has not developed in the 4 other patients with initial bone marrow involvement who received prophylactic intrathecal therapy.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone